Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EBITDA (2019 - 2025)

Bioadaptives' EBITDA history spans 7 years, with the latest figure at -$265689.0 for Q3 2025.

  • For Q3 2025, EBITDA fell 117.88% year-over-year to -$265689.0; the TTM value through Sep 2025 reached -$1.1 million, down 246.49%, while the annual FY2024 figure was -$602090.0, 163.01% down from the prior year.
  • EBITDA for Q3 2025 was -$265689.0 at Bioadaptives, up from -$279219.0 in the prior quarter.
  • Across five years, EBITDA topped out at -$18975.0 in Q1 2023 and bottomed at -$337339.0 in Q4 2024.
  • The 5-year median for EBITDA is -$121941.0 (2024), against an average of -$141213.1.
  • The largest annual shift saw EBITDA tumbled 897.05% in 2021 before it skyrocketed 89.11% in 2023.
  • A 5-year view of EBITDA shows it stood at -$177734.0 in 2021, then surged by 84.64% to -$27302.0 in 2022, then crashed by 126.3% to -$61784.0 in 2023, then crashed by 446.0% to -$337339.0 in 2024, then grew by 21.24% to -$265689.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's EBITDA are -$265689.0 (Q3 2025), -$279219.0 (Q2 2025), and -$249148.0 (Q1 2025).